BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
about
Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancerThe non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phaseInhibition of JNK by cellular stress- and tumor necrosis factor alpha-induced AKT2 through activation of the NF kappa B pathway in human epithelial CellsPhosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberinProtein kinase B is regulated in platelets by the collagen receptor glycoprotein VIPhosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligasePhosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progressionParadigms of growth control: relation to Cdk activation.Kynurenic acid inhibits colon cancer proliferation in vitro: effects on signaling pathways.Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity.Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosisBCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanismsSTI-571 in chronic myelogenous leukaemia.Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML.Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localizationGATA-1-mediated proliferation arrest during erythroid maturation.Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.Attenuation of choroidal neovascularization by histone deacetylase inhibitor.Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.P27kip1 regulates the apoptotic response of gastric epithelial cells to Helicobacter pylori.The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.Overexpression of N-myc downstream-regulated gene 1 inhibits human glioma proliferation and invasion via phosphoinositide 3-kinase/AKT pathwaysDNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells.Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrumPredicted mechanisms of resistance to mTOR inhibitors.Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.Breed-predispositions to cancer in pedigree dogs.CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis.Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduitsNickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo
P2860
Q24803723-CC3F29F8-3D25-441B-B139-4A84F3C087E6Q26749343-C9AC2A63-512D-45D8-A384-01FFE58E2770Q28202566-047CC111-B6C9-4D5C-BF5F-0C3F17FF22C1Q28217173-977EFE02-E75B-453B-8D2C-DB7948A07F92Q28217312-2087BEE9-7B69-4FFA-9459-54E16816F662Q28511501-8B91229C-63E7-41E7-B3D8-E761E00046F2Q30160146-05E86EC1-B694-42C8-9011-CE2233E7E36EQ33911230-6998AEE2-767E-4E6A-9303-51E8D31D3F6BQ34010802-D0361E6F-1FE7-4A71-AEB0-38BF117C67BBQ34130676-1559CD01-8653-4244-970D-80250CA7F3CBQ34208593-E794246E-C8C0-4A76-8A09-EE0DE3C131F5Q34271784-975BAEBA-BD8F-4C7E-A1B6-D04C712C89B9Q34281241-7A67CB57-35C0-4132-85ED-4158C9B4707EQ34441950-EF7BED49-9F18-4F92-8F17-A02E58EA1A44Q34551213-FFB17BDD-10E4-4E75-A9FA-0C2760FF0955Q34619261-D8CEE168-F8AE-4D0F-AA4D-9558151735F0Q34929139-C0168DD2-42F0-4A39-9A71-1538A83D4A8BQ35022530-4AFE38AC-761D-4E9D-B690-2D7F0029284CQ35083763-F308E600-73A6-43D9-A6B7-0F8C50C9C424Q35107812-39372FDF-2EA7-497D-99A8-F753CB45E7F5Q35166848-A05AD9C9-0896-4100-9D83-5493E2F69E7CQ35193024-0DCC0CA1-E466-4333-BC57-A1A5813FF363Q35217263-C766B01B-DC39-4B00-8F81-6B20CB41A886Q35510549-0D3DDD45-58E1-43F4-BE75-6BF7F6528E1EQ35596549-9DEF13E5-86A8-4F89-AA99-66E91CA02046Q35605737-2846EA1A-EB46-4227-9972-0AD71A768100Q35628577-0FD42DC1-C804-49CA-B380-CE1C8979016DQ36324767-FCD95797-025D-4C8B-AFD4-254A7BE44C37Q36398134-1EBD6D79-2A92-4328-B5D5-4F69DA33B9C3Q36403630-B4ECF456-E82E-4190-8203-C56D4B4EC8C8Q36585744-9BC63644-17F4-4CF2-82C7-1C8E8D5F40EAQ36695924-DEEEFC4D-7F7A-44F0-B80A-DB76BC1B4DC0Q36857180-239DAAE8-CAF7-4901-B5FA-DDEF023FC4DAQ36957067-2625EB1E-3399-4D59-BCE5-D55C4266DDF2Q37399824-9C9B2F90-0E9A-404D-A078-A41C6C36A867Q37421994-3FBB0C68-0054-477F-9DE4-21EAAD08192FQ37436738-06D2F29B-1216-49B6-820F-4EAA08EDB6FFQ37440054-41E56DEA-C964-426E-85D3-560BDEF125EDQ37454384-35722DD2-9F7B-4952-8E85-26F47175326FQ37483123-42B2EE7B-C23C-4ACF-BFB4-6142DFDEB406
P2860
BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
BCR/ABL regulates expression o ...... inositol 3-Kinase/AKT pathway.
@en
type
label
BCR/ABL regulates expression o ...... inositol 3-Kinase/AKT pathway.
@en
prefLabel
BCR/ABL regulates expression o ...... inositol 3-Kinase/AKT pathway.
@en
P2093
P2860
P356
P1476
BCR/ABL regulates expression o ...... inositol 3-Kinase/AKT pathway.
@en
P2093
J D Griffin
S Signoretti
W R Sellers
P2860
P304
39223-39230
P356
10.1074/JBC.M007291200
P407
P577
2000-12-01T00:00:00Z